Erin Burkhart's most recent trade in Biomarin Pharmaceutical Inc. - Registered Shares was a trade of 1,786 Common Stock done at an average price of $59.3 . Disclosure was reported to the exchange on May 19, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Biomarin Pharmaceutical Inc | Erin Burkhart | GVP, Chief Accounting Officer | 19 May 2025 | 1,786 | 14,173 (0%) | 0% | 59.3 | 105,928 | Common Stock | |
| Biomarin Pharmaceutical Inc | Erin Burkhart | GVP, Chief Accounting Officer | 19 May 2025 | 996 | 15,959 (0%) | 0% | 59.3 | 59,033 | Common Stock | |
| Biomarin Pharmaceutical Inc | Erin Burkhart | GVP, Chief Accounting Officer | 19 Mar 2025 | 1,295 | 16,955 (0%) | 0% | 71.5 | 92,618 | Common Stock | |
| Biomarin Pharmaceutical Inc | Erin Burkhart | GVP, Chief Accounting Officer | 14 Mar 2025 | 9,230 | 9,230 | - | - | Stock Option (Right to Buy Common Stock) | ||
| Biomarin Pharmaceutical Inc | Erin Burkhart | GVP, Chief Accounting Officer | 14 Mar 2025 | 5,970 | 18,252 (0%) | 0% | 0 | Common Stock | ||
| Biomarin Pharmaceutical Inc | Erin Burkhart | GVP, Chief Accounting Officer | 14 Mar 2025 | 823 | 12,282 (0%) | 0% | 69.4 | 57,149 | Common Stock | |
| Biomarin Pharmaceutical Inc | Erin Burkhart | GVP, Chief Accounting Officer | 24 Feb 2025 | 1,344 | 13,105 (0%) | 0% | 68.4 | 91,903 | Common Stock | |
| Biomarin Pharmaceutical Inc | Erin Burkhart | GVP, Chief Accounting Officer | 13 Aug 2024 | 714 | 14,449 (0%) | 0% | 90 | 64,260 | Common Stock | |
| Biomarin Pharmaceutical Inc | Erin Burkhart | GVP, Chief Accounting Officer | 17 May 2024 | 993 | 15,163 (0%) | 0% | 77.0 | 76,431 | Common Stock | |
| Biomarin Pharmaceutical Inc | Erin Burkhart | GVP, Chief Accounting Officer | 10 Apr 2024 | 2,286 | 16,156 (0%) | 0% | 90 | 205,740 | Common Stock | |
| Biomarin Pharmaceutical Inc | Erin Burkhart | GVP, Chief Accounting Officer | 15 Mar 2024 | 7,050 | 7,050 | - | - | Stock Option (Right to Buy Common Stock) | ||
| Biomarin Pharmaceutical Inc | Erin Burkhart | GVP, Chief Accounting Officer | 15 Mar 2024 | 4,720 | 18,814 (0%) | 0% | 0 | Common Stock | ||
| Biomarin Pharmaceutical Inc | Erin Burkhart | GVP, Chief Accounting Officer | 15 Mar 2024 | 372 | 18,442 (0%) | 0% | 83.9 | 31,200 | Common Stock | |
| Biomarin Pharmaceutical Inc | Erin Burkhart | GVP, Chief Accounting Officer | 16 May 2023 | 796 | 14,094 (0%) | 0% | 92.0 | 73,248 | Common Stock | |
| Biomarin Pharmaceutical Inc | Erin Burkhart | GVP, Chief Accounting Officer | 15 Mar 2023 | 5,720 | 5,720 | - | - | Stock Option (Right to buy Common Stock) | ||
| Biomarin Pharmaceutical Inc | Erin Burkhart | GVP, Chief Accounting Officer | 15 Mar 2023 | 3,760 | 14,890 (0%) | 0% | 0 | Common Stock | ||
| Biomarin Pharmaceutical Inc | Erin Burkhart | GVP, Chief Accounting Officer | 16 May 2022 | 17,490 | 17,490 | - | - | Stock Option (Right to buy Common Stock) | ||
| Biomarin Pharmaceutical Inc | Erin Burkhart | GVP, Chief Accounting Officer | 16 May 2022 | 11,130 | 11,130 (0%) | 0% | 0 | Common Stock |